序贯双期锥形束CT可在可降解淀粉微球经导管动脉化疗栓塞术过程中预测多灶性肝细胞癌一个月治疗结局
该前瞻性研究纳入24例肝细胞癌患者(96个病灶),在可降解淀粉微球经导管动脉化疗栓塞术(DSM-TACE)中行双期锥形束CT(DP-CBCT),以术后1个月多排CT的mRECIST评估为参考,分析病灶伪衰减值变化与治疗反应的相关性。ROC分析显示,第一次与第二次CBCT动脉期伪衰减差值预测完全缓解、客观缓解和总体疾病控制的截断值分别为>206 HU*、>72 HU*和>-7 HU*。结论认为DP-CBCT可通过评估病灶伪衰减变化在术中预测DSM-TACE的1个月治疗结局。
要点
- 术中两次DP-CBCT动脉期伪衰减差值>206 HU*可预测完全缓解(敏感度80.0%,特异度81.7%)。
- 动脉期伪衰减差值>72 HU*预测客观缓解(敏感度79.5%,特异度83.0%)。
- 动脉期伪衰减差值>-7 HU*预测总体疾病控制(敏感度91.6%,特异度65.4%)。
核心结论
- DP-CBCT可通过评估术中病灶伪衰减值变化,在DSM-TACE过程中预测1个月治疗结局。
研究设计与样本
- 前瞻性研究,2018年1月至5月纳入24例肝细胞癌患者(68.5±8.5岁,范围45-85岁),共96个病灶(平均4个/患者),行82次DSM-TACE。影像评估包括术前MDCT、术中第一次和第二次DSM-TACE前DP-CBCT以及术后1个月随访MDCT。病灶衰减/伪衰减定义为ROI平均测量值(MDCT为HU,CBCT为任意单位HU*)。以术后1个月MDCT的mRECIST标准为参考,分析病灶衰减变化与治疗反应的相关性。
关键影像表现/征象
- 术前MDCT动脉期衰减值为107.00 HU(95%CI 100.00-115.49),静脉期为85.00 HU(95%CI 81.13-91.74)。
- 第一次CBCT动脉期伪衰减值为305.00 HU*(95%CI 259.77-354.04),静脉期为155.00 HU*(95%CI 135.00-163.34)。
- 第二次CBCT动脉期伪衰减值为210.00 HU*(95%CI 179.47-228.58),静脉期为141.00 HU*(95%CI 125.47-158.11)。
- 术后MDCT动脉期衰减值为95.00 HU(95%CI 81.35-102.00),静脉期为83.00 HU(95%CI 78.00-88.00)。
诊断标准与关键数值
- 第一次与第二次CBCT动脉期伪衰减差值>206 HU*预测完全缓解,敏感度80.0%,特异度81.7%。
- 第一次与第二次CBCT动脉期伪衰减差值>72 HU*预测客观缓解(完全缓解+部分缓解),敏感度79.5%,特异度83.0%。
- 第一次与第二次CBCT动脉期伪衰减差值>-7 HU*预测总体疾病控制(客观缓解+疾病稳定),敏感度91.6%,特异度65.4%。
临床应用与阅片要点
- 术中行两次DP-CBCT并测量病灶动脉期伪衰减值,计算第一次与第二次的差值,可辅助预判DSM-TACE后1个月的治疗反应。
- 需注意CBCT伪衰减值单位为任意单位HU*,与MDCT的HU不可直接等同。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the prognostic value of sequential dual-phase CBCT (DP-CBCT) imaging performed during degradable starch microsphere TACE (DSM-TACE) session in predicting the HCC's response to treatment, evaluate with modify response evaluation criteria in solid tumours (mRECIST) at 1-month multi-detector CT (MDCT) follow-up.
MATERIALS AND METHODS: Between January and May 2018, 24 patients (68.5 ± 8.5 year [45-85]) with HCC lesions (n = 96 [average 4/patient]) were prospectively enrolled. Imaging assessment included: pre-procedural MDCT, intra-procedural DP-CBCT performed before first and second DSM-TACEs and 1-month follow-up MDCT. Lesions' attenuation/pseudo-attenuation was defined as average value measured on ROIs (HU for MDCT; arbitrary unit called HU* for CBCT). Lesions' attenuation modification was correlated with the post-procedural mRECIST criteria at 1-month MDCT.
RESULTS: Eighty-two DSM-TACEs were performed. Lesion's attenuation values were: pre-procedural MDCT arterial phase (AP) 107.00 HU (CI 95% 100.00-115.49), venous phase (VP) 85.00 HU (CI 95% 81.13-91.74); and lesion's pseudo-attenuation were: first CBCT-AP 305.00 HU* (CI 95% 259.77-354.04), CBCT-VP 155.00 HU* (CI 95% 135.00-163.34). For second CBCT were: -AP 210.00 HU* (CI 95% 179.47-228.58), -VP 141.00 HU* (CI 95% 125.47-158.11); and for post-procedural MDCT were: -AP 95.00 HU (CI 95% 81.35-102.00), -VP 83.00 HU (CI 95% 78.00-88.00). ROC curve analysis showed that a higher difference pseudo-attenuation between first and second DP-CBCTs is related to treatment response. The optimal cut-off value of the difference between first and second CBCT-APs to predict complete response, objective response (complete + partial response) and overall disease control (objective response + stable disease) were > 206 HU* (sensitivity 80.0%, specificity 81.7%), > 72 HU* (sensitivity 79.5%, specificity 83.0%) and > - 7 HU* (sensitivity 91.6%, specificity 65.4%), respectively.
CONCLUSIONS: DP-CBCT can predict intra-procedurally, by assessing lesion pseudo-attenuation modification, the DSM-TACE 1-month treatment outcome.
引用
- Lucatelli P, De Rubeis G, Basilico F, et al. Sequential dual-phase cone-beam CT is able to intra-procedurally predict the one-month treatment outcome of multi-focal HCC, in course of degradable starch microsphere TACE. Radiol Med. 2019. PMID: 31473930. doi:10.1007/s11547-019-01076-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。